Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass. and BASEL, Switzerland, June 27, 2022 (GLOBE NEWSWIRE) -- Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced...
-
CAMBRIDGE, Mass. and BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced...
-
CAMBRIDGE, Mass. and BASEL, Switzerland, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Enzyvant today announced the appointment of Johanna Rossell as Chief Commercial Officer. Johanna Rossell has an...
-
RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia Children with congenital athymia are born without a thymus...
-
On average, pediatric congenital athymia patients spent 150.6 days each year in the hospital with a mean total cost of $5,534,121 for supportive care over three years Mean total costs for...
-
Kaplan-Meier estimated survival at one year and two years post treatment with investigational RVT-802 was 77% and 76%, respectively Follow-up time in the Efficacy Analysis Set (EAS) ranged from 0...
-
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Enzyvant today announced the resubmission of the Biologics Licensing Application (BLA) to the U.S. Food and Drug Administration (FDA) for...